ATE462710T1 - Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert - Google Patents

Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert

Info

Publication number
ATE462710T1
ATE462710T1 AT03791618T AT03791618T ATE462710T1 AT E462710 T1 ATE462710 T1 AT E462710T1 AT 03791618 T AT03791618 T AT 03791618T AT 03791618 T AT03791618 T AT 03791618T AT E462710 T1 ATE462710 T1 AT E462710T1
Authority
AT
Austria
Prior art keywords
disease
crohn
fibrostenosis
fibrostenosing
nod2
Prior art date
Application number
AT03791618T
Other languages
English (en)
Inventor
Maria Abreu
Kent Taylor
Jerome Rotter
Huiying Yang
Kazuhito Sugimura
Stephan Targan
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ATE462710T1 publication Critical patent/ATE462710T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03791618T 2002-08-30 2003-07-30 Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert ATE462710T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40739102P 2002-08-30 2002-08-30
US10/356,736 US20040053263A1 (en) 2002-08-30 2003-01-30 Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
PCT/US2003/023926 WO2004020968A2 (en) 2002-08-30 2003-07-30 Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease

Publications (1)

Publication Number Publication Date
ATE462710T1 true ATE462710T1 (de) 2010-04-15

Family

ID=31981139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791618T ATE462710T1 (de) 2002-08-30 2003-07-30 Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert

Country Status (7)

Country Link
US (2) US20040053263A1 (de)
EP (1) EP1556405B1 (de)
JP (2) JP4606877B2 (de)
AT (1) ATE462710T1 (de)
AU (1) AU2003263834A1 (de)
DE (1) DE60331941D1 (de)
WO (1) WO2004020968A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828132B2 (en) * 2001-03-01 2004-12-07 Ultra Biotech Limited Biological fertilizer compositions comprising garbage
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
WO2005054853A2 (en) * 2003-12-03 2005-06-16 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
US20060205022A1 (en) * 2003-12-03 2006-09-14 Nir Dotan Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease
US7592150B2 (en) * 2003-12-03 2009-09-22 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
ES2336581T3 (es) * 2004-03-27 2010-04-14 Hanns-Georg Klein Polimorfismos en el gen nod2/card15.
US20080260753A1 (en) * 2004-04-09 2008-10-23 The Regents Of The University Of California Mouse Models of Crohn's Disease and a Method to Develop Specific Therapeutics
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
CA3204588A1 (en) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US10544459B2 (en) * 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
EP2049691A4 (de) * 2006-07-26 2010-06-16 Genizon Biosciences Inc Suszeptibilitätsgen für morbus crohn
CA2671267A1 (en) * 2006-11-30 2008-06-05 Navigenics Inc. Genetic analysis systems and methods
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2012135144A2 (en) * 2011-03-25 2012-10-04 Cedars-Sinai Medical Center Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease
EP2220507B1 (de) * 2007-11-30 2012-09-12 Glycominds Ltd. Zusammensetzung und verfahren zur vorhersage eines komplizierten krankheitsverlaufs und von operationen bei morbus crohn
WO2009143278A2 (en) * 2008-05-20 2009-11-26 Cedars-Sinai Medical Center Methods of diagnosing and characterizing cannabinoid signaling in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
NZ619527A (en) 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
WO2011088306A1 (en) * 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose crohn's disease
WO2012054532A1 (en) 2010-10-18 2012-04-26 Prometheus Laboratories Inc. Methods for determining anti-drug antibody isotypes
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4286517A3 (de) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
BR112017020750A2 (en) 2015-03-27 2018-06-26 President And Fellows Of Harvard College modified t-cells and methods of producing and using them
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
WO2020139748A1 (en) * 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
CN115087455A (zh) * 2019-11-12 2022-09-20 奥查德疗法(欧洲)有限公司 用于治疗或预防克罗恩病的组合物和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157053B2 (ja) * 1992-09-16 2001-04-16 ティーディーケイ株式会社 Ｄｎａ作用物質の結合様式特定方法
EP0615129B1 (de) * 1993-03-10 2000-05-31 Cedars-Sinai Medical Center Verfahren zum selektiven Nachweis von perinuklearen anti-neutrophilen cytoplasmischen Antikörpern bei ulzerativen Kolitis oder primärer sclerotischer Cholangitis
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6074835A (en) * 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US5916748A (en) * 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
WO1997038642A1 (en) * 1996-04-12 1997-10-23 Cedars-Sinai Medical Center Methods of determining the risk of pouchitis development
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
JP2001269196A (ja) * 2000-03-24 2001-10-02 Hamamatsu Photonics Kk 被検体核酸の定量方法、および被検体核酸の分子数の計数方法
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

Also Published As

Publication number Publication date
EP1556405B1 (de) 2010-03-31
AU2003263834A8 (en) 2004-03-19
US7790370B2 (en) 2010-09-07
WO2004020968A2 (en) 2004-03-11
DE60331941D1 (de) 2010-05-12
EP1556405A4 (de) 2007-01-10
JP2006500016A (ja) 2006-01-05
WO2004020968A3 (en) 2004-08-26
AU2003263834A1 (en) 2004-03-19
EP1556405A2 (de) 2005-07-27
US20040053263A1 (en) 2004-03-18
JP4606877B2 (ja) 2011-01-05
JP2011015686A (ja) 2011-01-27
US20070072180A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
DE60331941D1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
Striegel-Moore et al. Etiology of eating disorders in women
Stifano et al. Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
CA2282746A1 (en) Prediction of coronary artery disease
IL171020A (en) Methods for diagnosing or predicting susceptibility to types of crohn's disease
DE69941214D1 (de) DIAGNOSE, VORBEUGUNG UND BEHANDLUNG VON ULCERATIVER COLITIS UND DEREN SUBTYPEN UNTER VERWENDUNG MIKROBIELLER UC pANCA ANTIGENE
EP1718334A4 (de) Verfahren zur diagnose und behandlung von präeklampsie oder eklampsie
DE69231595D1 (de) Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom
Gehrman et al. Twin‐based heritability of actimetry traits
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
Kuo et al. FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in Kawasaki disease
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
Lynch et al. Performance measures in Friedreich ataxia: potential utility as clinical outcome tools
Meyer et al. Brief report: spatial heterogeneity of systemic sclerosis in France: high prevalence in the Northeast Region
Hansen et al. Diagnostic Thresholds for Ambulatory Blood Pressure Moving Lower: A Review Based on a Meta‐Analysis—Clinical Implications
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
Saleh et al. Predicting which patients with cirrhosis will develop overt hepatic encephalopathy: Beyond psychometric testing
DE60033646D1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
Hurko et al. Neurology and the skin
WO2003007801A3 (en) Diagnosis and treatment of vascular disease
EP1722225A4 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung
WO2002053018A3 (en) Method of detecting polymorphisms associated with breast carcinoma in mhc genes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties